Isoniazid (Ftivazide)

1.	Vernon, Andrew: 4 articles (05/2005 - 06/2002)
2.	Khuller, G K: 4 articles (09/2003 - 02/2001)
3.	Chaisson, Richard E: 3 articles (07/2007 - 06/2005)
4.	Yoshiyama, Takashi: 3 articles (02/2007 - 11/2006)
5.	Ito, Kunihiko: 3 articles (02/2007 - 11/2006)
6.	Peloquin, Charles A: 3 articles (12/2006 - 05/2003)
7.	Burman, William: 3 articles (05/2005 - 08/2002)
8.	Tuberculosis Trials Consortium: 3 articles (05/2005 - 08/2002)
9.	Benator, Debra: 3 articles (05/2005 - 08/2002)
10.	Khan, Awal: 3 articles (05/2005 - 08/2002)

Related Diseases

1.	Tuberculosis 01/01/1991 - "The parenteral administration of isoniazid in combination with other drugs was shown to be highly beneficial in disseminated form of tuberculosis in children." 05/01/1952 - "[Remarkable efficacy of isonicotinic acid hydrazide in a case of lingual tuberculosis and a case of ano-rectal tuberculosis.]" 04/01/2005 - "The optimal duration of preventive therapy with single drug isoniazid, daily or twice weekly, should be greater than six months to provide the maximum degree of protection against tuberculosis. " 06/01/2001 - "BACKGROUND: Isoniazid-resistant tuberculosis (INHr-TB) can be treated successfully with several treatment regimens. " 08/11/1997 - "CONCLUSIONS: Preventive therapy with isoniazid confers long-term protection against tuberculosis and significantly increases survival in patients dually infected with HIV and Mycobacterium tuberculosis." Order ALL the reference details at left...
2.	Pulmonary Tuberculosis 04/01/1996 - "OBJECTIVES: To compare the pharmacokinetic parameters and the clinical efficacy of isoniazid, administered in 10 mg/kg or 5 mg/kg to children suffering from pulmonary tuberculosis. " 11/15/2004 - "In these studies, the EBA of isoniazid during the first 2 days of treatment was determined for 97 patients with sputum smear-positive pulmonary tuberculosis following isoniazid doses of < or =37.5 mg, 75 mg, 150 mg, 300 mg, and 600 mg. The NAT2 genotype was determined in 70 patients, and the association between EBA and genotype was examined in this subgroup. " 01/01/2003 - "A complex approach to the therapy of patients with destructive pulmonary tuberculosis is suggested, within the study, with regard for the presence of multidrug-resistance of Mycobacterium tuberculosis (MBT), for a degree of inactivation of isoniazid and for a degree of bacterial-static activity of patient's blood, which provides for a higher treatment efficiency." 09/01/2001 - "In light of the study findings, and as per the recommendation of the World Health Organization, we suggest that a 4-drug regimen, as an initial treatment for pulmonary tuberculosis should be maintained, as resistance to isoniazid is still higher than the cut off value of 4%, and susceptibility testing for first line antituberculosis drugs should be carried out whenever possible. " 02/01/1977 - "1. The acetylator phenotype of over 600 pulmonary tuberculosis patients treated with intermittent isoniazid-containing regimens in two controlled clinical trials was determined using either sulphadimidine or a slow-release isoniazid formulation. " Order ALL the reference details at left...
3.	Infection 01/01/2005 - "According to the American Academy of Pediatrics, treatment of latent infection is highly effective with isoniazid administration for 9 months. " 06/01/1997 - "Other influences that may have diluted the efficacy of isoniazid include a high rate of transmission of new infection and rapid progression to disease or insufficient duration of isoniazid in subjects with relatively advanced immunosuppression. " 06/01/2006 - "Isoniazid preventive therapy (IPT) effectively treats latent TB infection (LTBI) and prevents progression to active TB. " 02/01/2000 - "Preventive treatment with isoniazid for 6-12 months is effective in reducing those with latent infection." 12/01/1998 - "Isoniazid is effective in the treatment of infection and prevention of progression of infection to clinical disease. " Order ALL the reference details at left...
4.	Seizures (Seizure) 08/01/1999 - "The results of these studies indicated that slow inactivator of isoniazid and its epileptogenic effects might contribute to the pathogenesis of myoclonic seizures in our patient." 08/01/2006 - "The extracts did not modify the latency to the first clonic convulsion or the survival time of isoniazid (210 mg/kg, ip)-treated mice. " 09/01/2005 - "Isoniazid (INH) has neurotoxic effects such as seizure, poor concentration, subtle reduction in memory, anxiety, depression and psychosis. " 02/01/2005 - "The activity against isoniazid-induced convulsions in mice after subcutaneous administration of the compounds was determined. " 02/01/2002 - "A 23-year-old with refractory seizures following an isoniazid overdose." Order ALL the reference details at left...
5.	Meningeal Tuberculosis (Tuberculous Meningitis) 01/01/2003 - "We report a case of refractory tuberculous meningitis which was markedly improved by intrathecal administration of isoniazid (INH). " 01/01/2003 - "[A case of refractory tuberculous meningitis markedly improved by intrathecal administration of isoniazid (INH)]" 06/01/1999 - "The psychosis resolved completely after completion of therapy for tuberculous meningitis and cessation of isoniazid. " 02/01/1953 - "[Chemical and biologic titration of isonicotinic acid hydrazide in the cerebrospinal fluid of children affected and cured of tuberculous meningitis.]" 02/01/1983 - "[Study of the csf isoniazid levels for the optimum isoniazid dosage for treating tuberculous meningitis in adults]" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Rifampin (Rifampicin)
2.	Pyrazinamide
3.	Streptomycin (Streptomycin Sulfate)
4.	Ethambutol (Myambutol)
5.	Tuberculin (PPD)
6.	p-Aminosalicylic Acid (PAS)
7.	Ofloxacin (Levofloxacin)
8.	Rifabutin (Ansamycin)
9.	Thioacetazone (Thiacetazone)
10.	Pyridoxine (Pyridoxin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Chemoprevention
3.	Retreatment
4.	Aftercare (After-Treatment)
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Tuberculosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 789 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>